Skip to main content

Table 1 Baseline characteristics of the patients in the aprotinin and tranexamic acid groups

From: Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis

 

Aprotinin

Tranexamic acid

 
 

Mean

SD

Mean

SD

P

Age (years)

     

All patients

68

11

67

11

0.09

Open-heart procedures

69

11

68

13

0.25

Height (cm)

     

All patients

171

9

172

9

0.88

Open-heart procedures

171

9

170

11

0.71

Weight (kg)

     

All patients

80

15

80

16

0.74

Open-heart procedures

77

17

77

15

0.94

Ejection fraction preop (%)

     

All patients

55

15

53

15

0.20

Open-heart procedures

53

14

51

16

0.18

Creatinine preop (mg/dL)

     

All patients

1.18

0.76

1.24

0.87

0.28

Open-heart procedures

1.14

0.46

1.31

1.03

0.04

Platelets preop (/nL)

     

All patients

235

88

239

80

0.51

Open-heart procedures

241

86

241

88

0.97

WBC preop (/nL)

     

All patients

8.3

4.2

8.1

2.9

0.37

Open-heart procedures

8.4

4.2

8.1

3.5

0.55

Hemoglobin preop (mg/dL)

     

All patients

13.6

1.8

13.1

2.0

< 0.01

Open-heart procedures

13.2

1.9

12.5

1.8

< 0.01

Prothrombin time preop (%)

     

All patients

93

15

93

14

0.69

Open-heart procedures

91

17

88

16

0.15

PTT preop (s)

     

All patients

41.1

23.7

42.3

24.0

0.49

Open-heart procedures

40.6

22.2

41.3

17.8

0.76

AT III preop (%)

     

All patients

97

15

95

17

0.17

Open-heart procedures

97

14

93

19

0.05

  1. AT III, antithrombin; PTT, partial thromboplastin time; SD, standard deviation; WBC, white blood cell count.